Related Experiment Video
Updated: Jun 14, 2026
10:08
Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
Published on: December 9, 2022
Benzyl prolinate derivatives as novel selective KCC2 blockers
Cécile Pégurier1, Nathalie Bosman, Philippe Collart
1UCB Pharma SA, UCB NewMedicines, Chemin du Foriest, B-1420 Braine-L'Alleud, Belgium.
Bioorganic & Medicinal Chemistry Letters
|March 20, 2010
Summary
Researchers discovered new selective KCC2 blockers, improving drug properties with a specific chemical modification. These findings advance the development of potential therapeutics targeting KCC2-related conditions.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Potassium-chloride cotransporter 2 (KCC2) plays a crucial role in neuronal function.
- Dysregulation of KCC2 is implicated in various neurological disorders.
- Developing selective modulators of KCC2 is a key therapeutic strategy.
Purpose of the Study:
- To discover and optimize a novel class of selective submicromolar KCC2 blockers.
- To characterize the structure-activity relationship (SAR) and pharmacokinetic properties of these compounds.
Main Methods:
- Synthesis of a novel series of prolinate derivatives.
- In vitro and in vivo assays to evaluate KCC2 blocking activity and selectivity.
- Assessment of Absorption, Distribution, Metabolism, and Excretion (ADME) properties.
Main Results:
- Identification of a novel class of selective KCC2 blockers with submicromolar potency.
- Structure-activity relationship studies revealed key determinants of activity.
- Optimization efforts led to compounds with improved overall general profiles, including favorable ADME properties.
- A methylsulfone residue on the R(1) phenyl group was identified as a beneficial modification.
Conclusions:
- A novel series of potent and selective KCC2 blockers has been successfully developed.
- The identified prolinate derivatives represent promising candidates for further therapeutic development.
- Chemical modifications, such as the introduction of a methylsulfone group, significantly enhance drug-like properties.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...